Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Hoenigl, M; Raggam, RB; Salzer, HJ; Valentin, T; Valentin, A; Zollner-Schwetz, I; Strohmeier, AT; Seeber, K; Wölfler, A; Sill, H; Krause, R.
Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.
Int J Antimicrob Agents. 2012; 39(6):510-513
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Hönigl Martin
Krause Robert
Raggam Reinhard Bernd
Salzer Helmut J. F.
Sill Heinz
Valentin Thomas
Wölfler Albert
Zollner-Schwetz Ines

Dimensions Citations:

Plum Analytics:
Posaconazole (PCZ) is a triazole antifungal agent that has broad activity against pathogenic fungi and is increasingly used for prophylaxis and treatment of invasive mould infections (IMIs). PCZ is only available as an oral formulation, with varying absorption from the gastrointestinal tract. However, reports correlating PCZ plasma concentrations (PPCs) with breakthrough IMIs are rare. In this study, PPCs were analysed in a prospective, observational, single-centre study and the correlation of PPCs with breakthrough IMIs in patients with haematological malignancies was evaluated. Risk factors associated with low PPCs were further evaluated. A total of 109 PPCs were measured in 34 cases receiving PCZ prophylaxis (n=31) or treatment (n=3). Levels below the target of 0.5 μg/mL were detected in 24 (71%) of the 34 cases; in 15 (63%) of these 24 cases concentrations were found to be <0.20 μg/mL. Three patients receiving PCZ prophylaxis met the criteria of breakthrough infection. Notably, prior to development of IMI, PPCs were below the target in all three individuals. Associated risk factors for insufficient PPCs varied from previous reports. In conclusion, these data demonstrate that therapeutic drug monitoring of PCZ is mandatory in all patients with haematological malignancies as low PPCs are common and may be associated with development of IMIs.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Antifungal Agents - blood
Aspergillosis - drug therapy
Chemoprevention -
Drug Monitoring -
Female -
Hematologic Neoplasms - complications
Humans -
Male -
Middle Aged -
Mycoses - blood
Risk Factors -
Triazoles - blood
Young Adult -

Find related publications in this database (Keywords)
Posaconazole plasma concentration
Antifungal prophylaxis
Antifungal therapy
Haematological malignancy
Therapeutic drug monitoring
© Meduni Graz Impressum